Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix Corporation (NASDAQ: QTRX) has appointed Laurie Olson to its Board of Directors, effective April 27, 2021. Olson brings over 30 years of pharmaceutical experience, having previously held key roles at Pfizer, including executive vice president of strategy and commercial operations. Her expertise in corporate strategy and market access aligns with Quanterix’s mission to advance precision health through innovative biomarker analysis. Olson's addition is expected to enhance the company's strategic direction as it seeks to leverage its Simoa technology for earlier disease detection and improved treatment.
Quanterix Corporation (NASDAQ:QTRX) announced a webinar set for April 23, 2021, focusing on advancements in neurological biomarkers such as pTau181 and pTau217. This session will feature prominent experts including CEO Kevin Hrusovsky and Dr. Charlotte Teunissen, discussing the opportunities presented by blood plasma biomarkers in conjunction with Simoa® technology for Alzheimer's Disease research. The event aims to highlight how these innovations can enhance clinical trials and diagnostics in the fight against Alzheimer's.
Quanterix Corporation (NASDAQ: QTRX) has appointed Shawn Stetson as interim CFO effective May 11, 2021, following Amol Chaubal's departure to Waters Corporation. The company is actively seeking a permanent successor. Kevin Hrusovsky, CEO, expressed confidence in Stetson's capabilities and acknowledged Chaubal's valuable contributions during his tenure. Quanterix focuses on digitizing biomarker analysis, offering innovative solutions aimed at enhancing healthcare delivery and disease detection, applicable in multiple therapeutic areas.
Quanterix Corporation (NASDAQ:QTRX) has reported successful utilization of its Simoa® technology for non-invasive detection of SARS-CoV-2 in various sample types. Published findings in Nature Communications suggest over 90% positive agreement and over 98% negative agreement with traditional PCR tests. The company emphasizes the importance of accurate, accessible testing amidst ongoing COVID-19 challenges. CEO Kevin Hrusovsky highlighted the potential for Simoa technology to enhance patient care and research, addressing issues like false negatives in current testing methods.
Quanterix Corporation (NASDAQ:QTRX) announced its ultra-sensitive Simoa technology was featured in 30 presentations at the AD/PD 2021 conference, showcasing its blood-based neurology biomarker assays. The findings emphasize the potential of these biomarkers, like phosphorylated tau and glial fibrillary acidic protein, as pre-screening tools for Alzheimer's and other neurodegenerative diseases, enabling earlier patient recruitment for clinical trials without costly procedures. CEO Kevin Hrusovsky highlighted the transformative capabilities of these tools, marking significant progress in precision health and potential opportunities for drug developers.
Quanterix Corporation (NASDAQ: QTRX) reported strong financial results for Q4 2020 and FY 2020, with total revenue of $26.1M for Q4, up from $15.9M in Q4 2019, and FY total revenue at $86.4M, compared to $56.7M in 2019. Key drivers include a NIH contract worth $18.2M to develop a SARS-CoV-2 test and FDA approvals for new COVID-related tests. The company’s product revenue also rose by 38% in Q4. Quanterix enhanced its biomarker analysis tools, notably for Alzheimer’s research, and raised approximately $385 million in funding, strengthening its financial position.
Quanterix Corporation (NASDAQ:QTRX) announced that its CEO, Kevin Hrusovsky, will present at the Cowen 41st Annual Health Care Conference on March 3 at 11:00 a.m. EST. A public webcast will be available at this link and will be accessible for 90 days post-event. Additionally, Hrusovsky will feature on the Health Care Rounds Podcast on February 26, discussing precision health. This episode airs at noon EST and will be available on major podcast platforms. Quanterix focuses on advancing precision health through digital biomarker analysis.
Quanterix Corporation (NASDAQ: QTRX) will announce its financial results for Q4 and full year 2020 after market close on March 2, 2021. Following the announcement, a conference call is scheduled for 4:30 p.m. ET, hosted by CEO Kevin Hrusovsky, to discuss the results and provide a business update. The call will be accessible via phone and a live webcast. Quanterix specializes in digitizing biomarker analysis aimed at advancing precision health.
Quanterix Corporation (NASDAQ: QTRX) will participate in the 10th Annual SVB Leerink Global Healthcare Conference, held virtually from February 22-26, 2021. CEO Kevin Hrusovsky's presentation is scheduled for February 26 at 9:20 a.m. EST. Interested parties can access the live webcast at this link or through the Investor section of Quanterix's website. The webcast will be available for replay for 90 days post-conference. Quanterix focuses on digitizing biomarker analysis to enhance precision health in various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced a strategic partnership with WuXi AppTec to establish a joint Simoa laboratory in Shanghai, enhancing biomarker testing access across China and the APAC region. This collaboration aims to leverage Quanterix' Simoa HD-X Analyzers and expertise to bolster pre-clinical and clinical research. Starting in 2021, researchers will gain access to Quanterix’ high-definition biomarker technology, which has previously supported over 800 projects. This initiative underscores the importance of biomarkers in advancing disease research and drug development.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?
What is the Simoa Accelerator Laboratory?
